Abstract：Objective: To explore the effect of vildagliptin on diabetic osteoporosis and microangiopathy in diabetic patients. Methods: 90 patients with diabetes treated in our hospital from November 2016 to November 2017 were selected as the subjects. The patients were divided into the control group and the observation group according to the random number table. The control group was treated with the routine treatment of diabetes. The patients in the observation group were treated with the treatment vildagliptin on the basis of routine treatment in the control group, and the comparison was two. The therapeutic effects were evaluated and the osteoporosis and microangiopathy in the two groups before and after treatment were evaluated. Results: After treatment, the FPG, 2hPG, HbAIC of the observation group were 5.3 ±1.1, 6.3±2.7 and 4.6±2.1, respectively. The bone mineral density of the observation group was 2.31±0.62, 2.29±0.57, 1.98±0.65 and 1.83±6.3, respectively. The number of vildagliptin retinopathy I, II, III and IV in the observation group after the treatment was significantly lower than that of the control group. The incidence of 40% was significantly lower than that of the control group. Conclusion: Vildagliptin's use in diabetic patients can help improve osteoporosis and microangiopathy in patients.
黄妙玲, 杜钢. 探讨维格列汀对糖尿病患者骨质疏松及微血管病变的影响[J]. 河北医学, 2019, 25(10): 1721-1723.
HUANG Miaoling, et al. Exploring the Effect of Vildagliptin on Osteoporosis and Microangiopathy in Diabetic Patients. HeBei Med, 2019, 25(10): 1721-1723.
2019, Vol. 25 
冀公网安备13080202000677号